field medical connect logo
  • Home
  • Psychiatry
  • Neurology
  • Connect with Field Medical
  • Custom Handout Builder
field medical connect logo
  • Home
  • Psychiatry
  • Neurology
  • Connect with Field medical
  • Custom Handout Builder

TAAR1: Trace Amine-Associated Receptors Animation


Video Transcript

[music]

Speaker 1: Trace Amines are the type of chemical messenger found in low levels in the brain, as well as in peripheral tissues. They are structurally, and metabolically related to the classical monoamine neurotransmitters, dopamine, serotonin, and Norepinephrine, and contribute to neurotransmitter systems in the brain. Trace Amines bind to a family of G protein-coupled receptors called TAARs. The most well-studied being TAAR1.

TAAR1 is widely distributed throughout the brain, including in dopamine-rich regions, such as the VTA, and Substantial Nigra, Serotonin-rich regions, like the DRN as well as in the prefrontal cortex, hypothalamus, and amygdala, areas important to the pathophysiology of various neuropsychiatric disorders. Due to extremely low expression levels, determining the precise localization of TAAR1 within cells has been challenging. Initial studies provide evidence for both intercellular and membrane localization of TAAR1, with TAAR1, found both pre and postsynaptically.

Functionally, TAAR1 has been implicated in the modulation of dopaminergic, serotonergic, and glutamatergic circuitry in the brain. Studies show complex crosstalk exists between TAAR1 and these neurotransmitter systems. For example, TAAR1 activation can reduce dopamine neuron firing, while TAAR1 inhibition enhances it. Additionally, TAAR1 activation can inhibit serotonergic neuronal firing in the DRN, and modulate Glutamatergic activity in the prefrontal cortex. TAAR1's ability to regulate neurotransmitter signaling in brain systems important for mood, psychosis, reward processing, and cognition suggest CIS potential as a therapeutic target for several neuropsychiatric disorders.

Future research may not only help us to characterize viable therapeutic targets but also may lead to a better understanding of the pathophysiology of diseases in which neurotransmission is compromised.

[music]

[00:02:50] [END OF AUDIO]

Related Content

Beyond the D2 Blockade: Trace Amine-Associated Receptor 1 as a Novel TAARget in Schizophrenia
Watch Video >
Trace Amine-Associated Receptor 1 (TAAR1)
View Infographic >
Negative Symptoms in Schizophrenia
View Infographic >
Sunovion and sunovion burst are registered trademarks of Sumitomo Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd.
©2023 Sunovion Pharmaceuticals Inc. All rights reserved.
SUNOVIONMEDICAL.COM
You are now leaving sunovionfieldmedical.com
cancel
continue
Please confirm below to continue:
I confirm that I am a Health Care Professional (HCP) practicing in the United States, or acting on behalf of an HCP.
OR
I am a Formulary Decision Maker (FDM) and/or working on behalf of a public or private payer organization to review scientific information to make drug or device selection or acquisition, formulary management, or coverage and reimbursement decisions on a population basis.

Sunovion Field Medical Opt-In

By clicking submit, I agree and acknowledge that the information I’ve provided voluntarily will be used only by Sunovion and its contracted third-parties to contact me regarding my request. I understand that Sunovion will not sell or transfer my name to any third party for their marketing use. Please see the most recent version of our privacy notice, which may change from time to time.

*Required

Share this resource

Here’s your message:
Please find a link below to Sunovion Health Insights, a website which contains information intended for U.S. fomulary decision-makers only: www.sunovionhealthinsights.com

The information you provide will be used by Sunovion Pharmaceuticals, Inc. in accordance with our Privacy Policy and by parties acting on behalf of Sunovion to send resources. View our Privacy Notice.